Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge

What Was Tested

This randomized controlled trial paper looks at Angiotensin II in the context of low blood pressure and orthostatic hypotension.

Telmisartan is a new angiotensin receptor antagonist possessing potent, selective, and insurmountable inhibitory activity specific to the angiotensin II type 1 (AT 1 ) receptor.

Diastolic and systolic blood pressure and pulse rate were recorded continuously using a servophotoplethysmograph.

Who Took Part

According to the abstract, 48 volunteers were involved.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

The Angiotensin II group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Aldosterone, Angiotensin II, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Area Under Curve, Benzimidazoles and Benzoates.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 48 volunteers in people with low blood pressure and orthostatic hypotension.

The publication is from 2001 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.